New indication for Syntara lead asset SNT-5505 as German MDS study group awarded A$2.5m grant to conduct phase 2 blood cancer trial

• Researchers at Heidelberg University to take SNT-5505 into the clinic for the blood cancers myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with A$2.5m funding from Deutsche Krebshilfe (German Cancer Aid)
• The phase 1b/2 study (AZALOX) in patients with high risk MDS and CMML will commence Q1 2025, running in parallel with the previously announced Australian phase 1c/2 study in low/intermediate risk MDS patients
• 7 German specialist centres have agreed to join the study, which has been prioritised by the German MDS Study Group. The grant will cover the cost of the study and Syntara will provide SNT-5505.
• The Phase 2 trials in myelofibrosis and MDS give SNT-5505 a combined blood cancer market opportunity of approximately US$6b

Click here to read more